Events › Healthcare & MedTech
Healthcare & MedTech
35
Exhibitors
850
Attendees
Animal Health, Nutrition and Technology Innovation Europe (AHNTI EU) is the premier innovation summit for the animal healthcare ecosystem, bringing together emerging startups, multinational pharmaceutical corporations, service providers, and venture capital investors.
Animal Health, Nutrition and Technology Innovation Europe is held annually. This page tracks the next confirmed edition — Animal Health, Nutrition and Technology Innovation Europe 2028 dates will be added here once announced.
Filter this event to your ICP.
35 exhibitors here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Venue
Royal Lancaster LondonHotel venue · 2,813 m² · 2 halls · ~1,500 people
A five-star luxury hotel in central London overlooking Hyde Park, featuring extensive event facilities including the Nine Kings and Westbourne Suites. Known for hosting large conferences, banquets, and galas, with 16-18 meeting rooms and total event space exceeding 30,000 sq ft, catering to up to 1,500 guests.
📍 Lancaster Terrace, London W2 2TY, United Kingdom
Operated by Rydges Hotels & Resorts
Organizer
Kisaco ResearchPrivate · London, United Kingdom · Founded 2013
Organizes high-level B2B events for industries including animal health, AI, and agriculture.
Why people attend
Senior executives, investors, and corporate development heads attend to source early-stage biotechnology investments, establish strategic licensing partnerships, and discover digital veterinary innovations.
Who attends
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
41 speakers at Animal Health, Nutrition and Technology Innovation Europe
Chief Executive Officer · Zoetis
Chief Executive Officer · Elanco
Also speaking at Carbon Capture Technology Expo North America, Hydrogen Technology Expo North America
Chief Executive Officer · Dechra
Executive Vice President, Global Strategy, Portfolio Marketing and Business Development, Global BioDevices and Platinum Performance · Zoetis
President · MWI Animal Health
SVP Global Operations · MSD Animal Health
Also speaking at North American Refining Technology Conference, Latin American Refining Technology Conference
Vice President of Business Development & External Innovation · Elanco
SVP Head of Global Strategic Marketing Animal Health · Boehringer Ingelheim
Group Chief Medical Officer · IVC Evidensia
Head of Global Business Development and Licensing Animal Health · Boehringer Ingelheim
Chief Veterinary Officer · CVS Group Plc
EVP Global Strategy and Market Development · Elanco
Head of Global Business Development · Merck Animal Health
CEO and Founder · Lupa
"Next Stage Two: Navigating Rapid Fundraising and Investor Momentum in Veterinary AI"
Securing $20 million in Series A funding just five months after its seed round, Lupa is redefining how AI transforms veterinary practice. Nicolo Frisiani, CEO of Lupa, shares how clear traction, rapid revenue growth, and a focus on customer success built strong investor confidence.
Chief Executive Officer · ELIAS Animal Health
"Next Stage One: Navigating the Commercialisation of Novel Cancer Therapies Amidst a Developing Regulatory Landscape"
When innovation moves faster than policy, the path to market calls for creative approaches. Tammie Wahaus, CEO of ELIAS Animal Health, shares how her team advances pivotal trials, adapts human health technologies, and keeps development on track as regulatory expectations continue to evolve.
CEO · Lupvindol Bioscience
"Next Stage Two: Navigating IP and Conditional Approval to Advance CBD–Corticosteroid Innovation"
Advancing a new therapeutic class to market requires a balance of strong science, solid IP protection, and a regulatory path that supports early access. Hunter Land (CEO) shares how Lupvindol is progressing its CBD–corticosteroid combinations for canine IBD and equine osteoarthritis through compelling efficacy data, robust patent strategy, and the FDA’s expanded conditional approval route.
Also speaking at Aspen Ideas Festival
+ 25 more speakers at this event.
More Healthcare & MedTech events
Frequently asked questions